Actuate Therapeutics, Inc.
ACTU Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.53
KIRA · Stoqly’s AI analyst, in plain words
- Actuate Therapeutics, Inc. lost $22.2M in fiscal 2025.
Market cap
$12.6M
P/E
—
Revenue
—
Net income
−$22.2M
Free cash flow
—
Operating margin
—
Actuate Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$22.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Actuate Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- ACTUATE THERAPEUTICS, INC.
- CIK
- 0001652935
Actuate Therapeutics, Inc. · ACTU
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$24.7M | −$27.3M | −$22.2M |
| Diluted EPS | −$17.24 | −$3.26 | −$1.06 |
| Cash | |||
| Cash from operations | −$21.6M | −$21.8M | −$19.2M |
| Share count change | — | 483.5% | 151.1% |
| Debt and strength | |||
| Cash and short-term investments | $3.0M | $8.6M | $13.2M |
| Shareholders' equity | −$99.6M | $0.1M | $7.9M |
| Current ratio | 0.4x | 1.0x | 2.4x |
| Interest coverage | −572.8x | −1,345.5x | −1,108.1x |
| Returns and quality | |||
| Return on equity | — | — | −553.7% |
| Return on tangible equity | — | −26,185.5% | −280.5% |
| Altman Z'' | −191.4 | −64.2 | −41.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.6M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Actuate Therapeutics, Inc. · ACTU
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.53 a share, the company is worth $12.6M.
Source: SEC EDGAR XBRL filings (CIK 0001652935). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.